![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M Raiteri, G Bonanno and F Vallebuona
Istituto di Farmacologia e Farmacognosia, Universita degli Studi di Genova, Italy.
The anorexigenic drug d-fenfluramine (d-F) increased the in vitro release of [3H]5-hydroxytryptamine ([3H]-5-HT) from rat hypothalamic synaptosomes. The release induced by 5 microM d-F was Ca(++)- independent, insensitive to 5-HT autoreceptor activation and prevented by the 5-HT uptake inhibitor fluoxetine (0.1 microM). The release evoked by 0.5 microM d-F also was blocked by fluoxetine, but it was Ca(++)-dependent and sensitive to autoreceptor activation. Thus, relatively high concentrations of d-F release 5-HT through an outward carrier mediated transport; at 0.5 microM the evoked release seems instead exocytotic, although it probably requires previous uptake of d- F by the 5-HT transporter. During in vivo intrahypothalamus microdialysis, in free-moving rats, local infusion (0.5 or 5 microM) or i.p. administration (0.8 or 2.5 mg/kg) of d-F produced increases of extracellular 5-HT. These effects were prevented completely by local (0.1 microM) or i.p. (1 mg/kg) administration of fluoxetine. Although both 0.8 and 2.5 mg/kg of d-F consistently increased hypothalamic extracellular 5-HT, only the higher dose induced hypophagia. This hypophagia was, however, not significantly modified by fluoxetine, although it was blocked by the 5-HT receptor antagonist metergoline (2 mg/kg i.p.). The results show that d-F is a potent 5-HT releaser also in the hypothalamus, one major site of action of the anorexigenic drug. Depending on the concentration, the release elicited by d-F may occur by a dual mechanism requiring integrity of the 5-HT transporter.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  R. B. Rothman, R. D. Clark, J. S. Partilla, and M. H. Baumann (+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1191 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Rowland, J. D. Roth, M. R. McMullen, A. Patel, and A. T. Cespedes Dexfenfluramine and norfenfluramine: comparison of mechanism of action in feeding and brain Fos-ir studies Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2000; 278(2): R390 - R399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Baumann, M. A. Ayestas, and R. B. Rothman Functional Consequences of Central Serotonin Depletion Produced by Repeated Fenfluramine Administration in Rats J. Neurosci., November 1, 1998; 18(21): 9069 - 9077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. EDDAHIBI, B. RAFFESTIN, J.-M. LAUNAY, M. SITBON, and S. ADNOT Effect of Dexfenfluramine Treatment in Rats Exposed to Acute and Chronic Hypoxia Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1111 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gundlah, K. F. Martin, D. J. Heal, and S. B. Auerbach In Vivo Criteria To Differentiate Monoamine Reuptake Inhibitors from Releasing Agents: Sibutramine Is a Reuptake Inhibitor J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 581 - 591. [Abstract] [Full Text]
|
|
|
|
|
|
U. D. Mccann, J. Yuan, G. Hatzidimitriou, and G. A. Ricaurte J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1487 - 1498. [Abstract]
|
|
 |
 |
 |
|
 |
 |
 |
